TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34657389
Drug: Perampanel 4
Normalized name: perampanel 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 4 mg/d during the Maintenance Period
Study: 34657389
Drug: Perampanel 4
Normalized name: perampanel 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 4 mg/d during the Titration Period
Study: 34659081
Drug: Prasinezumab, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasinezumab, dosage and duration not available
Study: 34659208
Drug: Allocetra™-OTS (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allocetra™-OTS (early apoptotic cell) infusion
Study: 34659886
Drug: Sintilimab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab monotherapy (2/3 L cohorts)
Study: 34659886
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus chemotherapy (1 L cohorts)
Study: 34659886
Drug: Sintilimab (2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (2/3 L cohorts)
Study: 34659886
Drug: Sintilimab alone
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab alone or combined with chemotherapy
Study: 34660302
Drug: Neoadjuvant Chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Chemotherapy (NCT) including adriamycin plus cyclophosphamide followed by intravenous docetaxel for 24 weeks
Study: 34660302
Drug: Neoadjuvant Endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant Endocrine Therapy (NET) involving goserelin acetate and daily tamoxifen for 24 weeks
Study: 34660654
Drug: KOKO Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: KOKO Plus (macronutrient- and micronutrient-fortified complementary food supplement)
Study: 34661885
Drug: upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: upadacitinib 15 mg QD and 30 mg QD
Study: 34662285
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) delivered via telemental health; details on dosage and duration not specified.
Study: 34663208
Drug: UST trough
Normalized name: Ustell
DrugBank: Phenyl salicylate (DB11071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UST trough concentration > 1.12 μg/mL
Study: 34663479
Drug: Initial serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial serum lactate > 5 mmol/L
Study: 34663479
Drug: Initial serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial serum lactate ≤ 5 mmol/L
Study: 34663638
Drug: Tremelimumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (75 mg intravenous) plus Durvalumab (1500 mg intravenous) every 4 weeks (up to four doses), followed by Durvalumab maintenance every 4 weeks (up to nine doses)
Study: 34663638
Drug: Post-treatment evaluation
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment evaluation of the bone microenvironment
Study: 34663650
Drug: Intensive rehabilitation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive rehabilitation programme (including physical, occupational, and speech therapy)
Study: 34664183
Drug: Microgynon (ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgynon (ethinylestradiol 30 μg and levonorgestrel 150 μg) administered before nintedanib and after nintedanib 150 mg twice daily for ≥ 10 consecutive days.
Study: 34664427
Drug: Mevidalen (titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mevidalen (titration from 15 to 75 mg)
Study: 34664531
Drug: Lanreotide PRF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide PRF (prolonged-release formulation) administered every 12 weeks
Study: 34664789
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (AAD) after catheter ablation for paroxysmal AF (n = 1051)
Study: 34664789
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (AAD) after catheter ablation for persistent AF (n = 641)
Study: 34664789
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic drug therapy (AAD) after catheter ablation for paroxysmal AF (n = 1087)
Study: 34664789
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic drug therapy (AAD) after catheter ablation for persistent AF (n = 496)
Study: 34665002
Drug: Immune-based treatment
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-based treatment
Study: 34665781
Drug: ABCB5+ MSCs
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABCB5+ MSCs (2 × 10^6 cells/kg) administered via 3 i.v. infusions on days 0, 17, and 35
Study: 34665810
Drug: Single 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 400 mg oral dose of Albendazole (ALB)
Study: 34665942
Drug: RC48 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RC48 2.5 mg/kg alone every 2 weeks
Study: 34666214
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with regional hyperthermia
Study: 34666347
Drug: CD30 CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD30 CAR T-cell therapy (CD30.CAR-T)
Study: 34666347
Drug: High metabolic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High metabolic tumor volume (MTV > 60 mL) before lymphodepletion and CD30.CAR-T infusion
Study: 34666347
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to bridging therapy
Study: 34666347
Drug: Percentage of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percentage of CD3+PD-1+ lymphocytes over the first 6 weeks of therapy
Study: 34666382
Drug: Maternal surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal surface electrode patch
Study: 34668977
Drug: Camrelizumab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab at 200 mg IV Q2W
Study: 34669164
Drug: Regular, twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular, twice-weekly voluntary PCR testing of health-care workers (HCW) and visitors in interventional nursing homes (INH)
Study: 34669183
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI; Acthar) 80 U subcutaneously twice weekly for 12 weeks followed by a 4-week taper
Study: 34670025
Drug: Continuation Magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation Magnetic Seizure Therapy
Study: 34670169
Drug: Pembrolizumab maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab maintenance therapy after ASCT
Study: 34670762
Drug: 30-item prefinal
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-item prefinal questionnaire administered electronically or by paper sheet.
Study: 34671131
Drug: Vinflunine 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinflunine 320 mg/m², 4 cycles
Study: 34671764
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Group Therapy
Study: 34672246
Drug: CD79-targeted chimeric
Normalized name: Chimeric Antigen Receptor T Cells targeting CD7
DrugBank: PA3-17 (DB18569)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD79-targeted chimeric antigen receptor (CAR) T-cell therapy
Study: 34673442
Drug: Bosutinib 400
Normalized name: bosutinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 400 mg/day
Study: 34673442
Drug: Bosutinib 300
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bosutinib 300 mg/day
Study: 34673442
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg/day (matched controls)
Study: 34673442
Drug: Bosutinib (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib (dose reduction)
Study: 34674490
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg nightly for 8 weeks
Study: 34674742
Drug: mRNA vaccine
Normalized name: RSV mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA vaccine Comirnaty® (Pfizer/BioNTech)
Study: 34674742
Drug: COVID-19 mRNA
Normalized name: COVID-19 mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 mRNA Vaccine Moderna®
Study: 34675018
Drug: Video game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video game therapy (VGT) on commercial video game console, 1 hour training session over 4 weeks (three sessions/week)
Study: 34675018
Drug: Video game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video game therapy (VGT)
Study: 34675018
Drug: Video game
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Video game therapy (VGT) and Standardised balance platform training (BPT)
Study: 34675020
Drug: Standard post-TP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard post-TP care and treatment
Study: 34675050
Drug: Progression index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progression index model based on tertiles of circulating concentrations of biomarkers (osteopontin, matrix metallopeptidase-7, intercellular adhesion molecule-1, periostin)
Study: 34675131
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment only
Study: 34675131
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment trends
Study: 34675476
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (RBZ) treatment, pro re nata regimen, mean number of injections 5.18 (range 2-6)
Study: 34675476
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (RBZ) treatment in non-vitrectomized eyes (group 2)
Study: 34675644
Drug: Fu's subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fu's subcutaneous needling (FSN) treatment
Study: 34675644
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation treatment
Study: 34675644
Drug: FSN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSN treatment
Study: 34676191
Drug: Daily disinfection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disinfection of the endoscopy unit
Study: 34678156
Drug: Overall positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall positive predictive value of biopsy using PSA threshold of 3.0 ng/mL
Study: 34678156
Drug: Overall positive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall positive predictive value of PSA threshold of 3.0 ng/mL
Study: 34678678
Drug: Trastuzumab alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab alone (4 mg/kg initial dose then 2 mg/kg weekly for 5 weeks)
Study: 34678678
Drug: Trastuzumab combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab combined with everolimus (10 mg/day for 6 weeks)
Study: 34678870
Drug: IC14 (atibuclimab)
Normalized name: IC14, (RECOMBINANT CHIMERIC MAB AGAINST HUMAN CD14)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC14 (atibuclimab) 2 mg/kg IV followed by 1 mg/kg/d IV × 3 (n=3)
Study: 34678870
Drug: IC14 (atibuclimab)
Normalized name: IC14, (RECOMBINANT CHIMERIC MAB AGAINST HUMAN CD14)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC14 (atibuclimab) 4 mg/kg IV followed by 2 mg/kg/d IV × 3 (n=7)
Study: 34684360
Drug: FIT2 program
Approvals — FDA: no, EMA: no, PMDA: no
Description: FIT2 program (smoking cessation therapy with individualized coaching in diet and physical activity strategies for PCWG restriction)
Study: 34686372
Drug: Maternal serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal serum albumin (MAlb) level <36.1 g/L
Study: 34686372
Drug: Maternal serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal serum albumin (MAlb) level >36.1 g/L
Study: 34686556
Drug: Daily screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily screening for sepsis using the 2007 American Burn Association diagnostic criteria
Study: 34686556
Drug: Daily multiple
Normalized name: Daily Multiple Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multiple organ dysfunction syndrome and Sequential Organ Failure Assessment Scores
Study: 34686642
Drug: PTSD comorbidity
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTSD comorbidity after 6 weeks of antidepressant use
Study: 34687040
Drug: Bamlanivimab 175-500
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab 175-500 mg
Study: 34687412
Drug: MRI measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI measures of subcutaneous adipose tissue in women with BCRL
Study: 34688250
Drug: Larotinib 350
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larotinib 350 mg
Study: 34688250
Drug: Larotinib 250
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larotinib 250 mg and 300 mg
Study: 34688250
Drug: Larotinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larotinib (all doses)
Study: 34688250
Drug: Larotinib (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larotinib (350 mg)
Study: 34688291
Drug: Quit Card
Normalized name: danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quit Card Intervention (QCI) - includes a 'Quit Card' worth $300 for nicotine replacement therapy, a self-help booklet, and 6 months of telephone follow-up counseling.
Study: 34690831
Drug: Transcranial Direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Direct Current Stimulation (tDCS), details on dosage and duration not available
Study: 34691243
Drug: Capecitabine in
Normalized name: Product containing capecitabine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine in combination with bendamustine
Study: 34692470
Drug: TTFields/TMZ combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTFields/TMZ combination
Study: 34692470
Drug: TMZ monotherapy
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ monotherapy
Study: 34693288
Drug: Macitentan 30
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan 30 mg to 300 mg once daily with TMZ
Study: 34693505
Drug: Tolvaptan (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan (15 mg/day, median treatment duration 18.5 days, range 1-1130 days)
Study: 34693508
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy initiated before the age of 5 years
Study: 34693508
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy initiated after the age of 5 years
Study: 34693508
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy achieving > 95% clearance
Study: 34693720
Drug: Ajmaline test
Normalized name: ajmaline
DrugBank: Ajmaline (DB01426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ajmaline test (1 mg/kg over 5 minutes)
Study: 34693994
Drug: Adjunctive counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive counseling by a health professional other than the physician
Study: 34693994
Drug: Cost-free smoking
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost-free smoking cessation medications
Study: 34694435
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in hs-cTnT values exceeding the biological variation defined by MID
Study: 34694529
Drug: Sasanlimab (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sasanlimab (intravenous at 1, 3, or 10 mg/kg every 3 weeks)
Study: 34694529
Drug: Sasanlimab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sasanlimab (subcutaneous at 300 mg every 4 weeks)
Study: 34694529
Drug: Sasanlimab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sasanlimab (both intravenous and subcutaneous)
Study: 34694911
Drug: Transcranial Rotating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Rotating Permanent Magnet Stimulator (TRPMS), 10 consecutive 40-minute treatment sessions.
Study: 34695615
Drug: Same-day intraprostatic
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day intraprostatic fiducial marker placement, perirectal hydrogel injection, and CT and MRI simulation
Study: 34696785
Drug: internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive behavioral therapy (iCBT) program combined with exercise therapy and education
Study: 34696785
Drug: exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: exercise therapy and education
Study: 34697109
Drug: Nadroparin overlapped
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin overlapped with warfarin
Study: 34697111
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of peg-IFN alpha 180 µg per week for 48 weeks combined with oral TDF 300 mg daily
Study: 34697111
Drug: TDF monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF monotherapy 300 mg oral daily
Study: 34697123
Drug: COMPASS (digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMPASS (digital cognitive-behavioural therapy programme) with six therapist contacts over 10 weeks
Study: 34699302
Drug: Electronic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic medication monitors (EMMs)
Study: 34699945
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) interventions
Study: 34700344
Drug: VEN 200
Normalized name: Inoven 200 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEN 200 mg and IBR 420 mg
Study: 34700344
Drug: All arms
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All arms (including various dosing combinations)
Study: 34700344
Drug: Higher dosing
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dosing combinations (IBR 560 mg and VEN 400 mg)
Study: 34702064
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (target SBP, 130-140 mm Hg)
Study: 34702064
Drug: Guideline-recommended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended treatment (target SBP <180 mm Hg)
Study: 34702124
Drug: VARIVAX™ 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: VARIVAX™ 0.5 mL (1 dose for ages 12 months-12 years; 2 doses 6 weeks apart for ages 13-17 years)
Study: 34702336
Drug: TAPER (Team
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAPER (Team Approach to Polypharmacy Evaluation and Reduction)
Study: 34702811
Drug: sintilimab 200
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab 200 mg intravenously every 3 weeks for up to 24 months
Study: 34706885
Drug: HIC-H patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIC-H patients treated with ICI monotherapy
Study: 34706885
Drug: HIC-C patients
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIC-C patients treated with ICI monotherapy
Study: 34706885
Drug: HIC-H patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIC-H patients treated with ICI plus chemotherapy
Study: 34706885
Drug: HIC-C patients
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIC-C patients treated with ICI plus chemotherapy
Study: 34711577
Drug: QuantiFERON test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: QuantiFERON test positive patients receiving antituberculosis treatment (ATT) for 6 months
Study: 34711577
Drug: QuantiFERON test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: QuantiFERON test value >2 IU/mL
Study: 34711577
Drug: QuantiFERON test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: QuantiFERON test threshold of 4 IU/mL
Study: 34711663
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of peptide vaccination with immune checkpoint inhibition
Study: 34711938
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) for 24-96 hours during the first 0-7 days after birth
Study: 34712113
Drug: Mesenchymal stromal
Normalized name: Mesenchymal Stromal Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stromal cells (MSCs) administered through the internal carotid arteries